If you are reading this, you already know what NAD+ is.

You've read Sinclair. You've listened to Attia. You've probably spent real money on NMN or NR. 

Many high-performing adults who track health metrics report that changes in energy consistency are not always fully explained by sleep, stress, or training variables alone. This observation has contributed to growing interest in NAD+ biology and cellular energy research.

The morning clarity that once carried through noon without friction — that uninterrupted runway of focus where the best decisions got made, the sharpest thinking happened — can feel shorter as professionals move through midlife. Many health-conscious professionals report noticing this pattern even when their routines remain relatively stable.

What the current scientific literature suggests most supplement brands have never fully addressed: the challenge may not be insufficient NAD+ intake. Studies point to a specific enzyme that may be degrading NAD+ before it completes the conversion process — and evidence suggests this enzyme becomes more active in the context of chronic physiological stress and normal aging.

The three gaps this literature has explored — and the formulation logic behind Niveo Bio — are what this article covers.

Marcus T., 41, runs a Series B venture-backed company in San Francisco. He sleeps 7.5 hours, tracks his HRV on an Oura Ring, trains Zone 2 four times a week, and had been taking premium NMN for two years.

On the advice of a longevity physician, he ran a private dry blood spot NAD+ panel. The result surprised him: his physician noted this pattern is commonly seen in high-performers who believe their protocol is working.

*Individual experience. NAD+ panels are not standard clinical tools; consult your healthcare provider. Results vary.*

The biochemical context behind that pattern — and why a single-compound approach may face an inherent ceiling — is something the research literature has been examining in increasing depth.

VIEW THE NIVEO BIO FORMULATION →

Gap One: The Conversion Ceiling

NMN and NR are well-researched compounds. The growing body of science presents a more nuanced picture than many supplement marketing messages emphasize — specifically around what happens after a precursor is swallowed.

Both NMN and NR must navigate multi-step enzymatic conversion pathways before becoming intracellular NAD+. Each step depends on specific enzymes functioning efficiently.

Studies examining aging tissue have observed that the rate-limiting enzyme in the primary NAD+ biosynthesis pathway — NAMPT — appears to decline with age. This means that even with robust precursor supplementation, the enzymatic machinery available to complete the conversion may be operating below its earlier capacity.

This conversion ceiling may help explain why some individuals see limited results despite consistent NAD+ precursor use — and why formulation approaches that bypass this pathway are an active area of interest.

Gap Two: The CD38 Challenge

CD38 is a membrane-bound enzyme found throughout the body, including in immune and vascular cells. Its role in acute inflammatory responses — brief infections, healing injuries — is a normal part of immune function.

The research interest centers on what may occur when low-grade chronic inflammation becomes a persistent background condition. The scientific literature refers to this as "inflammaging": the cumulative physiological toll of sustained stress, disrupted sleep, intense training cycles, and high-demand decision-making.

Preclinical and human aging studies have produced evidence suggesting that CD38 expression increases with age and with chronic inflammatory signaling — and that this increased expression may contribute substantially to age-associated cellular NAD+ decline.

Some published research positions CD38 overexpression as a more significant contributor to age-associated NAD+ decline than NAMPT reduction or increased PARP activity alone — though the relative contributions continue to be investigated.

An NMN capsule navigates the conversion pathway; some fraction becomes NAD+ and enters systemic circulation. But elevated CD38 activity may be continuously degrading NAD+ — potentially limiting how much reaches target tissues. The scientific literature describes this pattern as "filling the bucket while the drain is open."

Gap Three: The Sirtuin Activation Question

Even in a scenario where the conversion ceiling and CD38 activity were both addressed, a third gap appears in the NAD+ biology literature.

Sirtuin enzymes — particularly SIRT1 and SIRT3 — are molecular targets that use NAD+ as a co-substrate for cellular maintenance, epigenetic regulation, and mitochondrial quality control. Research has explored whether sirtuins benefit from not just substrate availability (NAD+) but also from direct allosteric interaction — specific compounds that interact with the enzyme's activation site and may enhance its functional engagement.

Without that signal, elevated NAD+ may remain underutilized at the cellular level. The substrate is available; the question is whether the machinery is fully engaged.

Three Gaps. One Formulation Framework.

• Gap One: Conversion ceiling. NAMPT appears to decline with age in studied tissue, which may limit how efficiently NAD+ precursors are converted — regardless of dose.
• Gap Two: CD38 degradation. Chronic inflammatory signaling may drive CD38 upregulation, continuously degrading NAD+ and potentially limiting how much reaches target tissues.
• Gap Three: Sirtuin activation. Research suggests that substrate availability alone may not be sufficient to fully engage sirtuin pathways — a direct allosteric activator may also be needed.

Many single-ingredient products focus primarily on substrate availability rather than multiple aspects of NAD+ biology. Formulation approaches vary considerably across the market.

Introducing Niveo Bio: A Three-Compound Approach

Niveo Bio is not an NAD+ precursor. It is a three-compound formulation designed to address all three gaps the scientific literature has explored — delivering direct NAD+ alongside ingredients studied for CD38 modulation and sirtuin pathway engagement.

Compound One: Direct NAD+ — 500mg

Niveo Bio delivers 500mg of structurally complete Nicotinamide Adenine Dinucleotide — the final, functional coenzyme — rather than a precursor requiring conversion. Direct NAD+ allows the formulation to provide the complete coenzyme rather than a precursor that requires multiple conversion steps. Designed to avoid dependence on precursor conversion pathways that involve enzymes such as NAMPT and NRK, whose activity changes with age. Whether orally delivered NAD+ reaches intracellular compartments efficiently in humans remains an active area of research.

Compound Two: Quercetin Dihydrate — 250mg

Quercetin is a polyphenolic flavonoid sourced from Sophora japonica — the Pagoda Tree — used for centuries in traditional Eastern wellness practices. Modern biochemistry has been investigating the molecular interactions that may underlie those traditional observations. Quercetin has been studied as a natural candidate for CD38 modulation and is a well-characterized antioxidant with an established body of preclinical research on inflammatory signaling pathways. This interaction has not been confirmed in large-scale human clinical trials; individual results vary.

Compound Three: Trans-Resveratrol (98% Extract) — 150mg

Trans-Resveratrol is derived from Japanese Knotweed (Polygonum cuspidatum), used historically in traditional Eastern practices to support vascular health and physical resilience. It has been studied extensively for its potential interaction with SIRT1's allosteric activation domain — specifically whether it may enhance sirtuin activity in the presence of NAD+. Preclinical research has explored whether this combined approach may support mitochondrial maintenance pathways, including those regulated by PGC-1alpha. Clinical confirmation in humans for these specific mechanisms remains an active area of study.

*On dietary Trans-Resveratrol: The 150mg of 98% pure Trans-Resveratrol in a single Niveo Bio serving would require quantities of dietary sources far beyond any realistic intake. Targeted supplementation is the only practical delivery method at studied concentrations.

What Users Report

*Individual results vary. The following are personal accounts and may not be typical. These experiences should not be interpreted as evidence that Niveo Bio will produce the same results for you. These statements have not been evaluated by the FDA.*

A Note On Tracking

Days 1–14: Establish a subjective baseline for afternoon energy consistency and focus. Some users begin noticing changes in the first two weeks; individual variation is significant.

Days 15–45: If using a sleep tracker, monitor deep sleep duration as a secondary indicator. Changes in subjective sleep quality are among the most commonly reported observations among consistent users of these compounds. This is not guaranteed.

The Formulation Case

Researchers continue to investigate how age-related changes in NAD+ biology are multifactorial, involving both lifestyle and cellular factors. Niveo Bio was formulated to address the cellular dimension of that picture — not to replace lifestyle inputs, but to work alongside them.

The remaining question is which formulation approach best aligns with an individual's wellness goals and interest in longevity research.

Who This Is For

Niveo Bio is not a mass-market wellness product. It is formulated for someone who follows the NAD+ and longevity research, understands that formulation approach matters as much as ingredient selection, and wants a protocol designed around the full picture the scientific literature describes.

The scientific literature has explored these three areas as potential factors influencing NAD+ biology. The formulation rationale is transparent. The remaining question is which formulation approach best aligns with an individual's wellness goals and interest in longevity research.